Titan Pharmaceuticals (TTNP.OB +7.8%) extends gains Monday after rising more than 30% Friday on news the FDA has recommended approval of the company's opioid addiction drug Probuphine. Investors however, are no doubt still stinging from the ~40% dive the stock took last Tuesday.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs